<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897856</url>
  </required_header>
  <id_info>
    <org_study_id>14-00050</org_study_id>
    <nct_id>NCT02897856</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures</brief_title>
  <official_title>Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to prove that intramuscular midazolam is more effective than buccal
      midazolam in cessation of seizure activity with comparable side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both buccal and intramuscular midazolam have been used to control seizures with variable
      succuss rates and side effects.

      In this study the investigators are going to assign patient randomly to receive either buccal
      or intramuscular midazolam. Then will compare both efficacy and side effect in both groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of seizure activity five minutes after treatment with study medication.</measure>
    <time_frame>five minutes</time_frame>
    <description>Cessation of abnormal motor activity with regaining of consciousness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major side effects.</measure>
    <time_frame>2 hours after cessation of seizures.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of seizure.</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of seizure activity within one hour after treatment with study medication.</measure>
    <time_frame>one hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Buccal midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intramuscular midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buccal midazolam</intervention_name>
    <description>Study subject will receive Buccal midazolam, Intramuscular placebo.</description>
    <arm_group_label>Buccal midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular midazolam</intervention_name>
    <description>Study subject will receive Intramuscular midazolam,Buccal placebo</description>
    <arm_group_label>intramuscular midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 6 month to 14 years who will be presented to the pediatric emergency or
             attended by emergency medical service who have active seizure and had no intravenous
             access would be eligible for the study.

        Exclusion Criteria:

          -  Cardiac arrest

          -  Head trauma

          -  Drowning

          -  Congenital heart disease

          -  Inborn errors of metabolism

          -  Electrolyte imbalance (hypocalcaemia, hyponatremia and hypoglycemia)

          -  Hemodynamic instability

          -  Allergy to benzodiazepines

          -  Focal seizures with preserved level of consciousness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Khalid Al-ansari, MD FRCPC FAAP</last_name>
    <phone>55336166</phone>
    <email>kalansari1@hamad.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magda Barkat, MD. FAAP.</last_name>
    <phone>66647614</phone>
    <email>magdabadawi@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad medical corporation</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Magda Barkat, MD,FAAP.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamad Medical Corporation</investigator_affiliation>
    <investigator_full_name>DR. KHALID AL-ANSARI</investigator_full_name>
    <investigator_title>Senior consultanat</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

